.

What is cross holding of shares ?

 The position when two companies each hold shares in
the other. If such holdings were of significant size this
would make it difficult for either company's
shareholders to displace the existing management; if
both were majority holdings it would be impossible to
vote out either set of directors so long as they agreed.
 In the most simple example of a cross holding,
Company X can hold stocks or bonds issued by
Company Y. Company Y's value would be counted
twice if the cross holding was not accounted for. It
would be counted once when looking at the value of
securities issued by the company, and again when
considering the securities held by Company X. This
would lead to having skewed information about the
values of companies on the index.
 The situation in which one publicly-traded company
 owns stock in another publicly-traded company. This
situation can lead to double-counting of securities,
especially when the two corporations are listed on the
same index. Thus, one needs to account for cross
holdings when aggregating the capitalizations of firms.
If two firms cross hold each other, it is difficult to
displace the management in one without the consent of
the other corporation.
 Share Holding Pattern
NO. OF TOTAL TOTAL NO. OF TOTAL SHARES
CATEGORY OF SHARE-HOLDERS NO. SHARES HELD IN SHAREHOLDING PLEDGED OR
SHARE OF DEMATERIALIZED AS A % OF TOTAL OTHERWISE
HOLDER SHARES FORM NO. OF SHARES ENCUMBERED
AS A % OF NUMBER OF
(A+B) SHARES
AS A % OF AS A % OF
(A+B+C) TOTAL
NO. OF
SHARES
(A) Shareholding of Promoter and Promoter Group

(1) Indian

(2) Foreign

Bodies Corporate 1 268,711,323 268,711,323 64.76 63.86 - -

Sub Total 1 268,711,323 268,711,323 64.76 63.86 - -

Total 1 268,711,323 268,711,323 64.76 63.86 - -

shareholding of
Promoter and
Promoter Group
(A)
(B) Public Shareholding
(1) Institutions
Mutual Funds / UTI 90 12,175,892 12,120,158 2.93 2.89
Financial 54 329,036 291,258 0.08 0.08
Institutions / Banks
Insurance 6 38,361,394 38,361,394 9.25 9.12
Companies
Foreign 210 32,432,210 32,423,978 7.82 7.71
Institutional
Investors
Sub Total 360 83,298,532 83,196,788 20.08 19.80
(2) Non-
Institutions

Bodies Corporate 2,294 13,389,893 13,344,575 3.23 3.18

Individuals - - - -

Individual 44,168,562 37,104,852 10.65 10.50

shareholders
holding nominal 167,894
share capital up to
Rs. 1 lakh

Individual 5,269,364 5,184,975 1.27 1.25

shareholders
holding nominal
74
share capital in
excess of Rs. 1
lakh
Any Others (Specify) 8 81,382 80,742 0.02 0.02 -

Foreign Corporate 81,382 80,742 0.02 0.02 -

8
Bodies

Sub Total 170,270 62,909,201 55,715,144 15.16 14.95 -

Total Public 170,630 146,207,733 138,911,932 35.24 34.75 -

shareholding (B)

Total (A)+(B) 170,631 414,919,056 407,623,255 100.00 98.61 -

(C) Shares held by 1 5,835,101 5,835,101 - 1.39 -

Custodians and against
which Depository
Receipts have been
issued-m

Total (A)+(B)+(C) 170,632 420,754,157 413,458,356 - 100.00 -

 5

4.5

3.5

3
Series 1
2.5 Series 2
2 Series 3

1.5

0.5

0
Category 1 Category 2 Category 3 Category 4
Sales

1st Qtr
2nd Qtr
3rd Qtr
4th Qtr
Ranbaxy Laboratories Ltd. M&A Summary

Ranbaxy Laboratories Ltd. has made 16 acquisitions while taking stakes in 13

companies. Ranbaxy Laboratories Ltd. has 6 divestitures during this period.
Year Acquisitions Stakes Divestitures
2009 1 0 0
2008 0 1 2
2007 1 3 0
2006 4 2 0
2005 1 1 0
2004 1 2 1
2003 0 1 1
2002 3 1 0
2001 0 1 0
2000 1 0 0
1999 0 0 1
1998 0 1 0
1997 2 0 1
1996 1 0 0
1995 1 0 0
Total 16 13 6
MD & CEO
Ranbaxy Laboratories Limited has informed the
Exchange that at the Board meeting of the Company
held on August 12, 2010 :(a). Mr. Atul Sobti has
stepped down from the position of CEO & Managing
Director of the Company effective August 19, 2010;
and (b).Mr. Arun Sawhney, currently President - Global
Pharmaceutical Business of the Company has been
appointed as Managing Director & CEO of the
Company for a period of three years effective August
20, 2010, subject to the approval of the shareholders.
 Mr. Sawhney is a veteran with over three decades of global
experience in the Chemical and Pharmaceutical industries.
He has held senior functional and management positions in
several global pharmaceutical companies like Max-Gb,
Hindustan Ciba-Geigy, Bayer India Limited and Dr.
Reddy’s Laboratories Limited.

Mr. Sawhney is one of the founder members of the

Pharmaceuticals Export Promotion Council (Pharmexcil)
and is currently a member of Advisory Board of USP in
India.

An alumnus of IMI, Delhi, he has done his graduation in

Commerce from Sydenham College of Commerce, Mumbai
University.
 Mr. Arun Sawhney, B.Com., PGDBM has been a
Managing Director of Ranbaxy Laboratories Ltd.
since August 20, 2010. Mr. Sawhney served as
President of Bulk SBU and Member of
Management Council of Dr. Reddy's Laboratories
Ltd. Mr. Sawhney started his tenure at Dr. Reddy's
in 2001, and served as its President - Europe and
Global of API business until May 5, 2008. Prior to
Dr. Reddy's Laboratories's he served as Chief
Executive Officer of Max-GB Ltd. Prior to that, Mr.
Sawhney Headed the Global Business Development
function at Ranbaxy Laboratories Limited.
Mr. Sawhney has also had successful stints as
Manager Exports with Hindustan Ciba Geigy and as
Regional Sales Manager with Bayer India, earlier in
his career. Mr. Sawhney has been a Director of
Ranbaxy Laboratories Ltd. since August 20, 2010. He
serves as Member of the Supervisory Board at
Terapia ,S.A.  Mr. Sawhney is a Silver Medalist of
MBA from the International Management Institute,
New Delhi and has a Bachelors degree in Commerce
from Sydenham College of Commerce and
Economics, Mumbai
THANK YOU

BY :
ANIRUDH JAIN
IV_BBM_C
0911251